These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10896900)

  • 1. The science, economics, and effectiveness of combination therapy for hepatitis C.
    Dusheiko G; Barnes E; Webster G; Whalley S
    Gut; 2000 Aug; 47(2):159-61. PubMed ID: 10896900
    [No Abstract]   [Full Text] [Related]  

  • 2. The economics of hepatitis C virus.
    Shah BB; Wong JB
    Clin Liver Dis; 2006 Nov; 10(4):717-34. PubMed ID: 17164114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy for hepatitis C infection.
    Newman TB
    N Engl J Med; 1999 Apr; 340(15):1207; author reply 1208-9. PubMed ID: 10206843
    [No Abstract]   [Full Text] [Related]  

  • 4. The science, economics, and effectiveness of combination therapy for hepatitis C.
    Read B
    Gut; 2001 Mar; 48(3):441. PubMed ID: 11256364
    [No Abstract]   [Full Text] [Related]  

  • 5. [Editorial commentary: Hepatitis C].
    Pár A
    Orv Hetil; 2015 May; 156(21):835. PubMed ID: 26038989
    [No Abstract]   [Full Text] [Related]  

  • 6. A pharmacoeconomic appraisal of therapies for hepatitis B and C.
    Younossi ZM; Temple ME; Shermock KM
    Expert Opin Pharmacother; 2001 Feb; 2(2):205-11. PubMed ID: 11336580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C.
    Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
    J Viral Hepat; 2010 Jan; 17(1):34-50. PubMed ID: 19656290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
    Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
    J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Because fee settlement means are not widely known. Deficits in hepatitis C therapy].
    MMW Fortschr Med; 2003 May; 145(19):55. PubMed ID: 12813986
    [No Abstract]   [Full Text] [Related]  

  • 10. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
    Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
    J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescribing practices for the treatment of hepatitis C in a Veterans Affairs medical center.
    Mangin EF; Jones WN
    Am J Health Syst Pharm; 2004 Jul; 61(14):1479-82. PubMed ID: 15332696
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients].
    Buti M; Gros B; Oyagüez I; Andrade RJ; Serra MA; Turnes J; Casado MA
    Farm Hosp; 2014 Sep; 38(5):418-29. PubMed ID: 25344136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
    Kim DD; Hutton DW; Raouf AA; Salama M; Hablas A; Seifeldin IA; Soliman AS
    Glob Public Health; 2015; 10(3):296-317. PubMed ID: 25469976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marketing scam spoils hep C treatment.
    Proj Inf Perspect; 1998 Dec; (26):6. PubMed ID: 11366498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there discrimination in access to therapy for HCV patients?
    Garattini S
    J Hepatol; 2008 Oct; 49(4):491-3. PubMed ID: 18678432
    [No Abstract]   [Full Text] [Related]  

  • 16. Ribavirin approved with a big fat price.
    Falkenberg J
    Notes Undergr; 1998; (No 37):10-1. PubMed ID: 11365818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Pricing Evolution in Hepatitis C.
    Vernaz N; Girardin F; Goossens N; Brügger U; Riguzzi M; Perrier A; Negro F
    PLoS One; 2016; 11(6):e0157098. PubMed ID: 27310294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany.
    Dintsios CM; Haverkamp A; Wiegand J; Gerlach T; Wedemeyer H; Pape G; Manns MP; Krauth C
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):278-88. PubMed ID: 19550347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New drugs for hepatitis C].
    Färkkilä M
    Duodecim; 2014; 130(18):1813-22. PubMed ID: 25558623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders.
    Nakamura J; Toyabe SI; Aoyagi Y; Akazawa K
    J Viral Hepat; 2008 Apr; 15(4):293-9. PubMed ID: 18307591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.